GREY:ATBPF - Post by User
Comment by
MrMugsyon Jan 18, 2023 10:09am
340 Views
Post# 35230394
RE:RE:Quiet day ...
RE:RE:Quiet day ...The next earnings report (late Feb ???) should indicate that cash was around $42.5 MM for the last quarter. That includes initial payment for the CITA sale.
As we understand it - the IBD candidate should have been selected and I can only assume we are waiting for the IP to be accepted at the patent office before they talk about it.
I'm looking for a few things w.r.t. the IBD drug ... that being ... how deep a solution it is ...
- Crohn's ???
- Colitis ???
- IBS ???
This will depend on the mechanisms employed ... H2S release, even release throughout the intestines (large and/or small), iron scavenging and any other mechanisms they may employ.
Solving the entire gut seems to be the key to all other problems - so - we need to get 346 and IBD right.
In terms of the share price ... nothing is more important than a perfect run at OTENA-acute (346). This is the catalyst that we need more than anything. So, we wait for GMP pills and we wait for PK Study in order to refine the Phase 2-Acute study. Also, these events are what opens the door to OTENA-chronic (determining if once a day at lower dose works - OR - if we need to look at sophisitcated regimen control to deal with the liver's personality).
Leave no money on the table (w.r.t. OTENA).
That's how I look at the events of 2023 unfolding.
All about mining the full value of this drug.
Good Luck !